About J. Christopher Love
Form D filings for Sunflower Therapeutics, PBC from 2022 to 2024 list J. Christopher Love as director.
J. Christopher Love first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name J. Christopher Love in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people J. Christopher Love works with at each company, as listed on that company's latest Form D.
Sunflower Therapeutics, PBC · Form D, May 24, 2024